Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Investment Securities (2016 - 2025)

UroGen Pharma (URGN) has disclosed Gains from Investment Securities for 10 consecutive years, with -$4.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 317.88% year-over-year to -$4.1 million, compared with a TTM value of -$3.4 million through Dec 2025, down 229.88%, and an annual FY2025 reading of $2.1 million, up 780.08% over the prior year.
  • Gains from Investment Securities was -$4.1 million for Q4 2025 at UroGen Pharma, down from $767228.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.9 million in Q4 2024 and bottomed at -$4.1 million in Q4 2025.
  • Average Gains from Investment Securities over 5 years is $462018.2, with a median of $854493.5 recorded in 2023.
  • Peak annual rise in Gains from Investment Securities hit 10160.0% in 2021, while the deepest fall reached 1184.31% in 2021.
  • Year by year, Gains from Investment Securities stood at -$553000.0 in 2021, then soared by 148.64% to $269000.0 in 2022, then soared by 416.73% to $1.4 million in 2023, then soared by 34.39% to $1.9 million in 2024, then crashed by 317.88% to -$4.1 million in 2025.
  • Business Quant data shows Gains from Investment Securities for URGN at -$4.1 million in Q4 2025, $767228.0 in Q2 2025, and -$218000.0 in Q1 2025.